Menu

Report Library

All Reports

Biomedtracker Early 2018 Outlook Report

February 01, 2018

In this report, we cover catalysts from 21 drugs expected to occur in Early 2018. For each drug, the likelihood of Phase/PDUFA review success and overall Likelihood of Approval (LOA) given their particular phase, drug class, and disease group are provided. The results of the catalysts highlighted in our Q4 2017 Outlook Report can be found on Page 4. At the end of this report, we have included a list of Large Impact catalysts through Early 2018.

For the full report, please download the PDF version at the top of this page. Additionally, the catalyst list is provided in Excel by downloading the supplemental material at the top of this page.

Interested in medical devices? Our sister product Meddevicetracker has published a concurrent report on 9 device catalysts expected to occur in Early 2018. This report can be downloaded for free here.


Like our report? Have any questions or feedback? Please let us know at askanalyst@sagientresearch.com.

For our disclosures, please read the Biomedtracker Research Standards.
Indications Covered: Alzheimer's Disease (AD)
Anesthesia
Brain Cancer (Malignant Glioma; AA and glioblastoma (GBM))
Chronic Lymphocytic Leukemia (CLL)/Small Cell Lymphocytic Lymphoma (SLL) - NHL
Cystic Fibrosis (CF)
Exocrine Pancreatic Insufficiency
HIV / AIDS Treatment
Immune Thrombocytopenic Purpura (ITP)
Major Depressive Disorder (MDD)
Moderate to Severe Pain
Neuroendocrine Tumors (NET)
Pancreatic Cancer
Prostate Cancer
Psoriasis
Spinal Muscular Atrophy
Systemic Lupus Erythematosus (SLE)
Uterine Fibroids
Uveitis (Ophthalmology)
X-Linked Hypophosphatemia (XLH)

 Additional Resources: